Quarterly ResultMay 6, 2026, 04:19 PM
Context Therapeutics Q1 Net Loss $8.7M; CTIM-76 Fast Track; Data Expected
AI Summary
Context Therapeutics reported a net loss of $8.7 million for the first quarter of 2026, an increase from $4.6 million in Q1 2025. The company announced significant pipeline progress, including FDA Fast Track Designation for CTIM-76 for platinum-resistant ovarian cancer. Interim Phase 1a data for CTIM-76 is expected in June 2026, and for CT-95 in September 2026. Cash and cash equivalents of $54.5 million as of March 31, 2026, are expected to fund operations into mid-2027.
Key Highlights
- Net loss for Q1 2026 was $8.7 million, compared to $4.6 million in Q1 2025.
- Cash and cash equivalents were $54.5 million as of March 31, 2026.
- Cash and cash equivalents are expected to fund operations into mid-2027.
- CTIM-76 received FDA Fast Track Designation for platinum-resistant ovarian cancer.
- Phase 1a interim data for CTIM-76 expected in June 2026.
- Phase 1a interim data for CT-95 expected in September 2026.
- Phase 1 initiation for CT-202 expected in Q3 2026 after Australian approval.
- R&D expenses increased to $7.0 million in Q1 2026 from $3.5 million in Q1 2025.
Price Impact
More from CNTX